Research To Practice | Oncology Videos Colorectal Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Nov 12, 2025
In this intriguing discussion, Dr. Chris Liu, an expert in colorectal cancer and immunotherapy, shares cutting-edge insights on neoadjuvant immune checkpoint inhibitors and their impressive results in MSI-high rectal cancer. He delves into the significance of recent trials, revealing high clinical response rates. Dr. John Strickler, a specialist in biomarker strategies, explores the role of minimal residual disease and the impact of targeted therapies like BRAF and KRAS. Both guests highlight the evolving landscape of colorectal cancer treatment and the importance of personalized approaches.
AI Snips
Chapters
Transcript
Episode notes
Brief Dual IO Drives Deep Pathologic Responses
- Short-course neoadjuvant dual checkpoint (nivolumab+ipilimumab) produced very high major and complete pathologic responses in MSI-high colon cancer.
- NICHE2 reported 95% major pathologic response and 100% three-year DFS in that cohort.
Use IO First For Metastatic MSI-High CRC
- Start frontline immunotherapy for newly diagnosed metastatic MSI-high colorectal cancer when eligible.
- Favor dual checkpoint (nivolumab+ipilimumab) in fit patients to maximize chance of long-term durable responses.
Liver Metastases Suppress IO Benefit
- Presence of liver metastases predicts poor immunotherapy response in MSS colorectal cancer.
- Non-liver metastatic sites (e.g., lung) show higher response rates and occasional durable benefit with IO combos.